Halaven

Type: Product
Name: Halaven
First reported Oct 22 2014 - Updated Oct 22 2014 - 3 reports

HER2 Positive Breast Cancer Drug Market to 2023: US, China and Japan Analysis With Forecasts

RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports for United States The says currently, treatment rates for HER2-positive breast cancer in China HER2-positive breast cancer ... [Published Industrial Info Financials - Oct 22 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Eisai launches online breast cancer resource

Research-based pharma firm Eisai has launched an online portal to provide resources to help women with metastatic breast cancer.The website, mbcInfoCenter.com, includes information on the disease, treatment options, an overview of common side effects ... [Published PMLive - Oct 16 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

Eisai announces launch of Halaven in Australia

Eisai Australia Pty. Ltd., a pharmaceutical sales subsidiary of Eisai Co., Ltd., has launched Halaven eribulin mesylate in Australia. Halaven is an anticancer agent discovered and developed by Eisai. It is currently approved in more than 55 countries ... [Published Individual.com - Oct 08 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 1 reports

New relief in breast cancer battle

Relief ... Breast cancer patient Robyn Moer now runs 6km a day after being treated with Halaven. Source: News Corp AustraliaA LIFE-EXTENDING new chemotherapy treatment that will help thousands of women with advanced breast cancer has been subsidised ... [Published Townsville Bulletin - Oct 04 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Roche could lose its dominant market share in breast cancer, says IMS report

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs, such as those from Swiss oncology giant Roche (ROG: SIX), according to a new webinar from IMS Health.Breast Cancer Targeting - Opportunities and Challenges ... [Published Pharma Letter - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Breast cancer drug sales will almost double by 2023, says IMS

Sales of breast cancer treatments are set to increase by an average of 5.8% a year in nine major markets, increasing from a value of $9.8 billion in 2013 to $18.2 billion by 2023, according to new forecasts from IMS Health. The highest-growing segment ... [Published Pharma Times - Oct 02 2014]
First reported Oct 01 2014 - Updated Oct 02 2014 - 2 reports

EISAI : Launches anticancer agent halaven in australia; first exclusively marketed product to mark commencement of full-scale operations

Release date- 01102014 - Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , ' Eisai ') announced today that its Australian pharmaceutical sales subsidiary Eisai Australia Pty. Ltd. (Eisai Australia) has launched Halaven (eribulin mesylate) in the ... [Published 4 Traders - Oct 02 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

ESMO 2014: Eisai’s Halaven could provide better quality of life for breast cancer patients

Data posters presented at this year’s European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, provide further evidence on the efficacy and quality of life profile of Halaven (eribulin) in the treatment of patients with locally advanced ... [Published Pharma Letter - Oct 01 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Halaven (Eribulin) Provides Clinical Benefit Without an Adverse Effect on Quality of Life: Data Presented at ESMO

/PRNewswire/ --FOR EMEA MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTSAdditional Pooled Phase III Data Presented at ESMO Show Significantly Improved Overall Survival for Eribulin Compared to Standard Therapies in Locally Advanced or Metastatic Breast Can ... [Published FinanzNachrichten.de - Sep 26 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

HALAVEN (Eribulin Mesylate) Injection [Eisai Inc.]

First reported Jul 07 2014 - Updated Jul 08 2014 - 2 reports

Eisai gets EC approval of indication expansion for Halaven to treat breast cancer

Japanese pharmaceutical firm Eisai has received approval from the European Commission (EC) of the indication expansion of Halaven (eribulin mesylate) to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who ... [Published BioPortfolio - Jul 07 2014]
First reported May 27 2014 - Updated May 27 2014 - 2 reports

Eisai's Halaven Eribulin Receives Positive CHMP Opinion for Advanced Breast Cancer After Only One Prior Chemotherapy

/PRNewswire/ -- FOREUMEDIA ONLY: NOT FOR SWISSMEDIA New indicationtobenefitthousands of women across Europe The European Medicines Agency's (EMA) Committee for Medi...Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: Eisai's Halaven ... [Published BioPortfolio - May 27 2014]

Quotes

"Cancer drugs are becoming increasingly expensive...primarily because a lot of the drugs that are coming through are what we could call a first in class" said Sarah Rawlings, PhD, assistant director of policy and information at Breakthrough Breast Cancer, a British charity
Release date- 01102014 - Eisai Co Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , " Eisai ') announced today that its Australian pharmaceutical sales subsidiary Eisai Australia Pty. Ltd. (Eisai Australia) has launched Halaven (eribulin mesylate) in the country."
Associate Professor Paul Mainwaring, medical oncologist at The Mater Hospital, Brisbane, said: "New treatment options for Australian women with locally advanced or metastatic breast cancer are welcomed by doctors, patients and their families as there remains a high unmet need for improved therapies. People who have been progressed on previous therapies urgently need new treatments that have demonstrated an overall survival benefit, so the availability of Halaven is very good news."

More Content

All (30) | News (26) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
HER2 Positive Breast Cancer Drug Market to 2023... [Published Industrial Info Financials - Oct 22 2014]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Indianapolis Business Journal - Oct 22 2014]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Scottrade - Oct 22 2014]
Eisai launches online breast cancer resource [Published PMLive - Oct 16 2014]
ASCO Clinical Practice Guideline: Chemotherapy ... [Published The ASCO Post - Oct 15 2014]
Metastatic Breast Cancer Awareness Day 2014 [Published Breastcancer.org - Oct 14 2014]
Cancer Drugs Fund in England: Plugging a Gap in... [Published American Journal of Public Health - Oct 09 2014]
Eisai announces launch of Halaven in Australia [Published Individual.com - Oct 08 2014]
New relief in breast cancer battle [Published Townsville Bulletin - Oct 04 2014]
Roche could lose its dominant market share in b... [Published Pharma Letter - Oct 03 2014]
Breast cancer drug sales will almost double by ... [Published Pharma Times - Oct 02 2014]
EISAI : Launches anticancer agent halaven in au... [Published 4 Traders - Oct 02 2014]
EISAI LAUNCHES ANTICANCER AGENT HALAVEN® IN AUS... [Published Eisai - Oct 01 2014]
ESMO 2014: Eisai’s Halaven could provide better... [Published Pharma Letter - Oct 01 2014]
Halaven (Eribulin) Provides Clinical Benefit Wi... [Published FinanzNachrichten.de - Sep 26 2014]
Lebanon Pharmaceuticals & Healthcare Report Q4 ... [Published Digital Journal - Sep 18 2014]
Eisai to present cancer drug data at ESMO 2014 [Published Zenopa - Sep 18 2014]
New Halaven (Eribulin) and Lenvatinib Data to b... [Published FinanzNachrichten.de - Sep 17 2014]
HALAVEN (Eribulin Mesylate) Injection [Eisai Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Eisai gets EC approval of indication expansion ... [Published BioPortfolio - Jul 07 2014]
Eisai gets EC approval of indication expansion ... [Published PBR - News - Jul 07 2014]
Expanded EU approval sets Halaven on course [Published BioPortfolio - Jul 03 2014]
Eisais breast cancer drug Halaven receives MAA ... [Published BioPortfolio - Jul 03 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 12 2014]
Eisai's Halaven Eribulin Receives Positive CHMP... [Published BioPortfolio - May 27 2014]
Eisai Receives Positive Opinion from EMA's CHMP... [Published BioPortfolio - May 27 2014]
Pending EC decision: Halaven, eribulin, Opinion... [Published Pending EC decisions and European Public Assess ... - May 23 2014]
Eisai announces availability of Halaven in Leba... [Published BioPortfolio - Apr 07 2014]
Eisai's lenvatinib to follow in Nexavar's foots... [Published BioPortfolio - Feb 04 2014]
The Pixie Awards Announces 2014 Competition Win... [Published PRWeb - Jan 23 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
HALAVEN (Eribulin Mesylate) Injection [Eisai Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Updated Date: Aug 15, 2014 EST ...
Eisai gets EC approval of indication expansion ... [Published PBR - News - Jul 07 2014]
Japanese pharmaceutical firm Eisai has received approval from the European Commission (EC) of the indication expansion of Halaven (eribulin mesylate) to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jun 12 2014]
Pending EC decision: Halaven, eribulin, Opinion... [Published Pending EC decisions and European Public Assess ... - May 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.